ASX healthcare stock Vitrafy Life Sciences Ltd (ASX: VFY) has been one of the hottest shares in 2026.
The company has designed and developed an innovative solution to advance cryopreservation, including smart devices, a quality management software platform, and smart packaging solutions.
Commercial success has led to significant share price gains of almost 150% in 2026 alone.
A new report from Bell Potter suggests this is likely to continue, with the broker significantly increasing its 12-month price target.
Image source: Getty Images
$30 million capital raise
Vitrafy recently raised $30 million from institutional investors at $2.60 per share.
Following this, the company announced a Share Purchase Plan (SPP).
The company said the SPP intends to raise up to $2 million.
The SPP provides Eligible Shareholders with the opportunity to acquire new fully paid ordinary shares in the Company ("New Shares") at the same price as the institutional placement announced to the ASX on Friday, 12 June 2026, which raised A$30 million.
Each Eligible Shareholder may apply for up to A$30,000 worth of New Shares at the offer price of A$2.60 per New Share, irrespective of the size of their holding in Vitrafy, without incurring brokerage or transaction costs.
What is Bell Potter's view?
Following this announcement, the team at Bell Potter provided updated guidance on this ASX healthcare stock.
The broker largely appears constructive/bullish on the capital raise, viewing it as growth funding rather than a rescue financing.
According to the report, commercial traction is improving, with positive developments in military blood studies, animal reproduction partnerships, and growing interest from the U.S. civilian blood market.
The $32 million total raise (A$30m placement + A$2m SPP) provides enough capital to manufacture approximately 100 units and accelerate commercial deployment.
Bell Potter estimates those units could generate around A$12 million of annual managed-service revenue, plus recurring consumable sales.
Target price increase for ASX healthcare stock
This ASX healthcare stock closed trading yesterday at $3.19 per share.
The team at Bell Potter have now upgraded their 12-month price target to $5.15 (previously $3.00).
It has retained its speculative buy recommendation.
This indicates an upside potential of 61% from current levels.
The capital raising and developments in the Red Blood Cell market have instigated a revision to our estimates, particularly from FY28 on the revenue line, where we see 175 total units being installed by FY30 which could generate $80m in annual revenue.
We still anticipate VFY reaching breakeven by FY30.
